| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 862.68 | 8.3% | 10.0% |
| Total Income | 862.68 | 8.3% | 10.0% |
| Expenditure | 767.27 | 15.1% | 7.4% |
| PBT | 15.06 | 78.8% | 388.5% |
| Net Profit | -21.70 | 137.6% | 1015.6% |
| OPM | 11.06% | 5.24pp | 2.09pp |
| NPM | -2.52% | 9.76pp | 2.82pp |
| EPS | -0.06 | 133.3% | 700.0% |
Amneal Reports Q3 2026 Financial Results with Increased Guidance
03 Nov 2026 · 3 Nov, 6:42 pm
Summary
Amneal Pharmaceuticals announced its third quarter 2026 results, reporting a 10% increase in net revenue to $863 million year-over-year, driven by strong performance in Affordable Medicines and Specialty segments. Despite a GAAP net loss of $22 million, primarily due to acquisition and integration costs, the company saw a 30% increase in Adjusted EBITDA to $207 million and a 53% rise in Adjusted Diluted EPS to $0.26. Amneal is updating its full-year 2026 guidance upwards for net revenue, adjusted EBITDA, and adjusted diluted EPS, reflecting confidence in its accelerating financial performance and growth outlook.
Key Highlights
- 1
Amneal reported third quarter 2026 net revenue of $863 million, an increase of 10% compared to $785 million in the third quarter of 2025.
- 2
Affordable Medicines net revenue increased 19% and Specialty net revenue increased 20% in Q3 2026.
- 3
Net loss attributable to Amneal Pharmaceuticals, Inc. was $22 million in Q3 2026, compared to a net income of $2 million in Q3 2025.
- 4
Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of 30% compared to the third quarter of 2025.
- 5
Adjusted diluted earnings per share in Q3 2026 was $0.26, an increase of 53% compared to $0.17 for Q3 2025.
- 6
The company is increasing its full year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS.
Management Comments
Chirag and Chintu Patel
Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT®, and BREKIYA® autoinjector. The Kashiv integration is proceeding well, and we are excited about the long-term growth potential in biosimilars. With the breadth and depth of opportunities across our portfolio, we remain highly confident in Amneal’s robust growth outlook.
Informational and educational content only. Not investment advice.